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Background: Tyrosine kinase inhibitors (TKIs) have experienced a tremendous boost in the last decade, where
more than 15 small molecule TKIs have been approved by the FDA. Unfortunately, despite their promising clinical
successes, a large portion of patients remain unresponsive to these targeted drugs. For non-small cell lung cancer
(NSCLC), the effectiveness of TKIs is dependent on the mutational status of epidermal growth factor receptor (EGFR).
The exon 19 deletion as well as the L858R point mutation lead to excellent sensitivity to TKIs such as erlotinib and
gefitinib; however, despite initial good response, most patients invariably develop resistance against these first-
generation reversible TKIs, e.g., via T790M point mutation. Second-generation TKIs that irreversibly bind to EGFR
wild-type and mutant isoforms have therefore been developed and one of these candidates, afatinib, has now
reached the market. Whether irreversible TKIs differ from reversible TKIs in their in vivo tumor-targeting properties is,
however, not known and is the subject of the present study.
Methods: Erlotinib was labeled with carbon-11 and afatinib with fluorine-18 without modifying the structure of these
compounds. A preclinical positron emission tomography (PET) study was performed in mice bearing NSCLC xenografts
with a representative panel of mutations: an EGFR-WT xenograft cell line (A549), an acquired treatment-resistant
L858R/T790M mutant (H1975), and a treatment-sensitive exon 19 deleted mutant (HCC827). PET imaging was
performed in these xenografts with both tracers. Additionally, the effect of drug efflux transporter permeability
glycoprotein (P-gp) on the tumor uptake of tracers was explored by therapeutic blocking with tariquidar.
Results: Both tracers only demonstrated selective tumor uptake in the HCC827 xenograft line (tumor-to-background
ratio, [11C]erlotinib 1.9 ± 0.5 and [18F]afatinib 2.3 ± 0.4), thereby showing the ability to distinguish sensitizing mutations
in vivo. No major differences were observed in the kinetics of the reversible and the irreversible tracers in each of the
xenograft models. Under P-gp blocking conditions, no significant changes in tumor-to-background ratio were
observed; however, [18F]afatinib demonstrated better tumor retention in all xenograft models.
Conclusions: TKI-PET provides a method to image sensitizing mutations and can be a valuable tool to compare the
distinguished targeting properties of TKIs in vivo.
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Recent developments in molecular biology have led to
an increased understanding of the signal transduction
pathways in cancer, and crucial molecular targets have
been identified that are involved in cancer growth, sur-
vival, and metastasis. Furthermore, increased structural
understanding of proteins and their specific chemical in-
teractions combined with high throughput screening
and medicinal chemistry efforts has led to major break-
throughs in drug discovery. Together, this has led to the
development of tailor-made targeted pharmaceuticals as
anti-cancer drugs. Receptor tyrosine kinases (RTKs)
form a family of transmembrane proteins that have re-
ceived a lot of interest as they play a pivotal role in the
signal transduction pathways of the cell. RTKs consist of
an extracellular domain capable of ligand binding and an
intracellular domain for downstream signaling. Promin-
ent members of this family include the epidermal growth
factor receptor (EGFR) and the vascular endothelial
growth factor receptor (VEGFR) [1,2].
The development of small molecules targeting kinases
has expanded enormously in the last decade. Over 15
small molecule tyrosine kinase inhibitors (TKIs) have
been approved by the US Food and Drug Administration
with an estimated several hundreds under (pre)clinical
development. These TKIs act on the intracellular cata-
lytic kinase domain by competing with ATP and induce
inhibition of downstream signaling [3]. Good cell pene-
tration and long-lasting, high-affinity binding to the
RTK are required to effectively compete with the high
intracellular ATP concentration [4]. Although the ap-
proval rate of new TKIs is high and substantial patient
benefit is achieved, there is a lack of long-term efficacy
in certain patients with RTK-driven tumors. The under-
lying cause of this inter-patient variability is best under-
stood for EGFR-targeting kinase inhibitors in non-small
cell lung cancer (NSCLC) [5].
Activating mutations in the kinase domain of EGFR
dictate effectiveness of TKIs that are currently on the
market. The most common sensitizing mutations are
small in-frame deletions in exon 19 (45%) or the L858R
missense mutation (40% to 45%) in exon 21 leading to
favorable response rates to EGFR TKIs [6]. As a result,
EGFR TKI therapy is especially effective in NSCLC pa-
tients with tumors displaying an activating EGFR muta-
tion which occurs in 5% to 25% of the Caucasian
NSCLC patient population [7,8]. In clinical practice, mu-
tational status is determined by an invasive biopsy of the
tumor tissue, which does not always provide a represen-
tative overview of the genomic heterogeneity of the
tumor [9]. Unfortunately, despite initial promising re-
sponse, most patients develop resistance against first-
generation reversible TKIs such as erlotinib and gefitinib
[10]. About half of the recurrences are associated withthe occurrence of an additional point mutation, i.e., the
exon 20 T790M, which compared to the single EGFR
mutant, displays increased affinity for ATP and thus re-
duced affinity for first-generation reversible inhibitors.
Second-generation TKIs such as dacomitinib or afati-
nib that covalently bind to EGFR have been developed,
and afatinib has recently obtained marketing approval
for first-line treatment of lung cancer patients with com-
mon activating EGFR mutations [11]. This new gener-
ation of inhibitors not only binds covalently to their
target molecules but also inhibits all kinase-competent
members of the ErbB receptor family, which are EGFR,
HER2, and ERBB4. Most mutant isoforms of these ErbB
receptors including EGFR T790M are also inhibited by
these new molecules, which therefore bear the potential
to delay or even circumvent some of the resistance
mechanisms set off by first-generation inhibitors [1].
In recent publications we, among others, have demon-
strated the use positron emission tomography (PET) im-
aging with radiolabeled TKIs (TKI-PET) as a tool to
address TKI disposition in vivo. By labeling the TKI with
a positron emitting radionuclide and maintaining its ori-
ginal structure, these PET tracers can be used to assess
the in vivo biodistribution, pharmacokinetics (at tracer
level), off-target binding, and more importantly tumor
targeting of the therapeutic itself by means of PET
[12,13]. TKI-PET could also become a technique to
identify patients who might benefit from treatment, thus
providing a non-invasive predictive tool for personalized
medicine [3,12,13]. However, whether irreversible TKIs
differ from reversible TKIs in their in vivo tumor target-
ing properties, is not known and is subject of this study.
Erlotinib (Tarceva®, Roche, Basel, Switzerland; 1, Figure 1)
is a first-generation reversible 4-anilinoquinazoline inhibi-
tor of EGFR and was approved in 2004 for NSCLC treat-
ment of patients with locally advanced or metastatic
NSCLC in combination with chemotherapy. No patient se-
lection based on mutation analysis was performed at the
time of approval and all eligible NSCLC patients were
treated with erlotinib [14]. In the following years, it became
clear that EGFR mutations are of great importance for the
efficacy of erlotinib (and other first-generation EGFR TKIs,
such as gefitinib), and erlotinib was subsequently approved
in 2013 as a first-line treatment for patients whose tumors
harbor an exon 19 deletion or an exon 20 point mutation
[15]. TKI-PET imaging with the tracer [11C]erlotinib was
first reported by Memon et al. in a seminal study demon-
strating selective uptake in treatment-sensitive xenografts
with mutation-activated EGFR. In this pre-clinical study,
no metabolite analysis was performed [16]. Subsequently, a
clinical evaluation was performed by the same group in
NSCLC patients demonstrating uptake in a subgroup of
patients; however, in that study, mutational status was not
reported [17]. The first proof-of-principle in a clinical study
Figure 1 Chemical structures of erlotinib and afatinib.
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tients with responsive EGFR exon 19 deleted tumors
showed increased uptake of [11C]erlotinib when compared
to patients with non-responsive EGFR wild-type tumors.
Furthermore, in these patients, a metabolite analysis was
performed demonstrating circa 50% intact [11C]erlotinib in
plasma and mainly polar metabolites. This was the first
study ever demonstrating the predictive potential of an
EGFR TKI-PET tracer; therefore, this tracer was used as
‘gold standard’ reference in this study [18].
Afatinib (Giotrif/Gilotrif®, Boehringer Ingelheim, Ingel-
heim, Germany; 2, Figure 1) is a second-generation irre-
versible 4-anilinoquinazoline inhibitor of EGFR [19]. By
virtue of its Michael acceptor moiety, it is an irreversible
inhibitor, which acts by covalent binding to a cysteine
residue in the ATP binding domain of EGFR (Cys 797),
HER2 (Cys 805), and ERBB4 (Cys 803) [19,20]. It can be
hypothesized that the covalent binding of afatinib to
EGFR could result in longer retention in the tumor as
compared to the reversible TKI erlotinib and could thus
provide a PET probe with improved tumor retention.
Afatinib has recently gained approval for the treatment
of patients with metastatic NSCLC whose tumors harbor
common EGFR-activating mutations [11].
We recently reported the fluorine-18 labeling of afati-
nib and initial preclinical evaluation [21]. These studies
demonstrated excellent in vivo stability of the tracer,
with over 80% of intact [18F]afatinib present 45 min
post injection (PI) in the blood plasma. Uptake in
NSCLC xenografted mice was also observed. These
achievements now allow for the first time the direct
comparison of the tumor-targeting potential of the
first-generation reversible TKI [11C]erlotinib and the
second-generation irreversible TKI [18F]afatinib, both
approved for the treatment of NSCLC. The aim of this
study was to determine whether irreversible TKIs have
improved tumor-targeting properties and kinetics and
to investigate the influence of drug efflux transporters
on the tumor uptake kinetics of these compounds.Methods
Cell lines and reagents
Human lung cancer cell lines A549, H1975, and HCC827
were obtained from the American Type Culture Collec-
tion. Erlotinib was obtained from Sequioa Research Prod-
ucts (Pangbourne, UK), and afatinib was obtained from
Axxon Medchem (Groningen, The Netherlands).
Xenografts
Female athymic nude mice (20 to 25 g) (Harlan Laborator-
ies, Horst, The Netherlands) were housed in sterile cages
under standard conditions (24°C, 60% relative humidity,
12-h light/dark cycles) and provided with water and food
ad libitum. All reported studies were performed according
to the national regulation and approved by the local animal
experiments ethical committee (VU University Medical
Center animal experimentation ethics committee). Sub-
cutaneous tumors were induced by inoculating approxi-
mately 2 × 106 cells of the A549, H1975, or HCC827 cell
lines on the left flank. Approximately 1 to 2 weeks after
tumor cell inoculation, the tumors were of suitable size
(100 to 200 mm3).
Sequencing of xenografts
EGFR mutation analysis was performed on DNA isolated
from xenografts using high-resolution melting followed
by cycle sequencing of PCR products displaying a sus-
pect melting profile, as described before [22].
Immunohistochemical staining
Cryosections of frozen xenografts (A549, H1975, and
HCC827) were immunostained for the assessment of
EGFR and permeability glycoprotein (P-gp) expression.
Antibodies were diluted in phosphate-buffered saline
(PBS) with 1% bovine serum albumin. EGFR was stained
with cetuximab (Merck & Company, Whitehouse Sta-
tion, NJ, USA) and P-gp with rabbit polyclonal anti-P-
gp (AB103477, ITK Diagnostics BV, Uithoorn, The
Netherlands). As secondary antibodies, rabbit anti-
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A/S, Glostrup, Denmark) or swine anti-rabbit horserad-
ish peroxidase (P0217, Dako) were used. Cryosections
(5 μm) of fresh frozen (tumor) tissue were air-dried and
subsequently fixed with 2% paraformaldehyde in PBS
for 10 min. The sections were blocked with normal
rabbit serum (in case of cetuximab) or with normal
swine serum (in case of anti-P-gp) and subsequently
stained with cetuximab 10 μg/mL (EGFR) or anti-P-gp
5 μg/mL. Color development was performed with di-
aminobenzidine (DAB) and counterstaining was done
with hematoxylin.
Synthesis of radiotracers
[11C]erlotinib [18] was synthesized as previously de-
scribed (Scheme 1). Briefly, cyclotron-produced [11C]
CO2 was reduced using LiAlH4 to obtain [
11C]CH3OLi
and the latter was subsequently halogenated using
hydrogen iodide. The obtained [11C]MeI was distilled to
a new vessel containing the hydroxyl labeling precursor
3 (1.0 mg, 2.5 μmol) and tetrabutylammonium hydrox-
ide (TBAOH, 5 M aqueous solution, 2 μL, 10 μmol) as a
supporting base in acetonitrile (250 μL). The alkylation
is performed for 5 min at 120°C. The product was iso-
lated by semi-preparative high-performance liquid chro-
matography (HPLC), carried out on a Jasco PU-2089
pump (Jasco Inc. Easton, MD, USA) equipped with a
SymmetryPrep C-18 (Waters Corporation, Milford, MA,
USA; 7 μm, 300 mm × 7.8 mm) using MeCN/25 mM so-
dium phosphate buffer pH = 3.5 (30:70, v/v) as eluent at
a flow rate of 4.3 mL/min, a Jasco UV1575 UV detector
(λ = 254 nm) and a custom-made radioactivity detector.
Chromatograms were acquired using ChromNAV soft-
ware (version 1.14.01, Jasco). The collected fraction of
the preparative HPLC purification containing the prod-
uct was diluted with 40 mL of aqueous NaOH (1 mM),
and the total mixture was passed over a tC18 Plus Sep-
Pak cartridge. The cartridge was then washed with
20 mL of sterile water after which the product was
eluted from the cartridge with 1.0 mL of sterile 96%
ethanol. The ethanol was diluted to 10 vol.% with for-
mulation solution (7.09 mM NaH2PO4 in 0.9% NaCl, w/
v in water, pH 5.2), and the complete solution was fil-
tered over a Millex-GV 0.22-μm filter into a sterile
20 mL capped vial to provide a final solution of 10%Scheme 1 Radiosynthesis of [11C]erlotinib. TBAOH, tetrabutylammoniumethanol in saline (containing 7.09 mM NaH2PO4) con-
taining [11C]erlotinib in >99% radiochemical purity as an
intravenous (IV) injectable solution in a total synthesis
time of less than 30 min (from end of isotope produc-
tion) in high specific activity (287 ± 63 GBq/μmol) and
in 13.1% ± 3.7% yield (corrected for decay, up to 3 GBq
isolated).
[18F]afatinib [21] was synthesized as previously re-
ported (Scheme 2). Briefly, cyclotron-produced [18F]
fluoride was azeotropically dried with acetonitrile/water (9/
1, v/v) containing K[2.2.2] (4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane, 13.0 mg, 34.6 μmol) and po-
tassium carbonate (2.0 mg, 15 μmol). To the dried residue
was added a solution of 3-chloro-4-trimethylammonium-
nitrobenzene triflate (4, 3.0 mg, 14 μmol) in acetonitrile
(0.7 mL), and the mixture was allowed to react for 25 min
at 40°C. After the reaction mixture was quenched with
water (7 mL), 3-chloro-4-[18F]fluoronitrobenzene ([18F]5)
was trapped on a tC18 Plus Sep-Pak, rinsed with water
(10 mL), and subsequently eluted with MeOH (1.5 mL)
into a screw cap reaction vessel containing palladium on
activated carbon (10%, 3 mg) and sodium borohydride
(10.0 mg, 264 μmol). The reduction was carried out for
7 min at 20°C upon which the reaction was quenched by
the addition of concentrated hydrochloric acid (37%,
0.1 mL). The thus obtained mixture was passed through a
syringe filter (Millex LCR PTFE 0.45 μM/25 mm; Millipore
Corporation, Darmstadt, Germany) into a new screw cap
reaction vessel. The volatiles were removed in vacuo and
under a helium flow (100 mL/min) at elevated tempera-
tures (90°C for 5 min and 120°C for 2 min) to obtain the
dry 3-chloro-4-[18F]fluoroaniline-HCl salt ([18F]6). The
product was dissolved in N-methylpyrrolidine (NMP,
0.5 mL) and to this solution was added a solution of
(S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-
3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide (7,
2 mg, 6 μmol), benzotriazole-1-yl-oxy-tris-(dimethyla-
mino)-phosphonium hexafluorophosphate (BOP), 5.5 mg,
12 μmol, and 1,8-diazabicyclo[5.4.0]undec-7-een, 2.7 μL
(DBU), 18 μmol, in anhydrous NMP (0.5 mL), which was
dissolved 15 min prior to addition. The obtained mixture
was heated to 120°C for 30 min after which it was cooled
to 20°C. The product was isolated by semi-preparative
HPLC, carried out on a Jasco PU-2089 pump equipped
with a C18 Alltima column (Grace, 5 μm, 250 mm×hydroxide; DMF, dimethylformamide.
Scheme 2 Radiosynthesis of [18F]6 and subsequent condensation towards [18F]afatinib. MeCN, acetonitrile; MeOH, methanol; DBU, 1,8-
diazabicyclo[5.4.0]undec-7-een; NMP, N-methylpyrrolidone.
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MeCN/H2O/DiPA (40:60:0.2, v/v/v) as eluent at a flow
rate of 4 mL/min, a Jasco UV1575 UV detector (λ =
254 nm), and a custom-made radioactivity detector. Chro-
matograms were acquired using ChromNAV software
(version 1.14.01, Jasco). The collected fraction of the pre-
parative HPLC purification containing the product was di-
luted with 50 mL of water and the total mixture was
passed over a tC18 Plus Sep-Pak cartridge. The cartridge
was then washed with 20 mL of sterile water after which
the product was eluted from the cartridge with 1.0 mL of
sterile 96% ethanol. The ethanol was diluted to 10 vol.%
with formulation solution (7.09 mM NaH2PO4 in 0.9%
NaCl, w/v in water, pH 5.2), and the complete solution
was filtered over a Millex-GV 0.22-μm filter into a sterile
20 mL capped vial. In this way, a final IV injectable solu-
tion was provided of 10% ethanol in saline (containing
7.09 mM NaH2PO4) containing [
18F]afatinib obtained at
>98% radiochemical purity, in a total synthesis time of less
than 120 min (from end of isotope production), at a high
specific activity (287 ± 63 GBq/μmol), and in 17.0% ± 2.5%
yield (corrected for decay, up to 3.5 GBq isolated).
PET imaging
Dynamic PET imaging was performed on three cancer
xenograft lines (A549, H1975, and HCC827) in nude mice.
Each mouse (n = 3) carried one tumor, which was located
on the left flank. Imaging was performed for a duration of
90 ([11C]erlotinib) or 120 min ([18F]afatinib) using a
double-LSO/LYSO-layer high-resolution research tomo-
graph (HRRT; CTI/Siemens, Knoxville, TN, USA). Themice were anesthetized with 4% and 2% isoflurane in 1 L/
min oxygen for induction and maintenance, respectively.
First, for attenuation and scatter correction, a transmission
scan was acquired using a 740-MBq two-dimensional (2D)
fan-collimated 137Cs (662 keV) moving point source. Next,
a dynamic emission scan was acquired immediately follow-
ing administration (IV ocular plexus) of 8 to 10 MBq [11C]
erlotinib (223 ± 38 GBq/μmol) or 4 to 6 MBq [18F]afatinib
(287 ± 63 GBq/μmol) to each animal. Positron emission
scans were acquired in list mode and rebinned into the fol-
lowing frame sequence: 10 × 60 s, 4 × 300 s, and 9 × 600 s.
After the TKI scan was finished, [18F]FDG was adminis-
tered (IV ocular plexus) to the mice followed by scanning
for another 60 min. Following corrections for decay, dead
time, scatter, and randoms, the scans were reconstructed
using an iterative 3D-ordered subsets weighted least-
squares analysis (3D-OSWLS). The point source resolution
varied across the field of view from approximately 2.3- to
3.2-mm full width at half maximum in the transaxial direc-
tion and from 2.5 to 3.4 mm in the axial direction. Post-
filtering was not performed after reconstruction. The PET
images were analyzed using the freely available AMIDE
software version 0.9.2 (a medical imaging data examiner). A
box was drawn over the complete animal to obtain the
image-derived percentage injected dose per gram (%ID/g).
Regions of interest (ROIs) containing the tumor tissue as
well as a reference area, which was drawn in the opposite
flank of the animal containing exactly the same tissue only
devoid of tumor cells, were drawn using the [18F]FDG data;
the tumor region was defined as FDG positive voxels of the
tumor. Subsequently, the corresponding images obtained
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activity-curve (TAC) was plotted for both the tumor as well
as the reference area. The images were smoothed using a
Gaussian filter (2 mm).
For PET imaging studies using mass amounts, afatinib
(1.0 mg) was dissolved in DMSO (1.0 mL) and diluted
with formulation solution (7.09 mM NaH2PO4 in 0.9%
NaCl, w/v in water, pH 5.2) to the appropriate concen-
trations (40, 120, 400, and 1,200 nM), and after addition
of 50 μL [18F]afatinib to 50 μL of these solutions, they
were injected as a IV bolus.
For the P-gp blocking experiments, tariquidar (7.5 mg/
mL, Azatrius Pharmaceuticals Pvt. Ltd. Mumbai, India)
was diluted to 3.75 mg/mL with saline for injection. In
the blocking experiments, tariquidar (15 mg/kg) was ad-
ministered IV 20 min prior to tracer injection [23].Statistical analysis
Statistical analysis on tumor-to-background ratios was
performed using Graphpad PRISM (v 5.02, Graphpad
Software Inc). The concentration of activity in the tumor
(%ID/g, n = 3 per group) was compared to the concen-
tration of activity in the reference tissue using a one-
tailed Student’s t-test for paired data.Results and discussion
Radiochemistry
The synthesis of [11C]erlotinib has been described previ-
ously and involves a straightforward alkylation employ-
ing [11C]MeI on a terminal alcohol (3) depicted in
Scheme 1, providing [11C]erlotinib in high radiochemical
yields (up to 4 GBq) and high specific activity (287 ±
63 GBq/μmol) [18].
The synthesis of [18F]afatinib (Scheme 2) was recently
published by our group and involves a BOP-mediated
coupling of 3-chloro-4-[18F]fluoroaniline ([18F]6) with 7
as a key step [21]. The synthesis of [18F]afatinib starts
with nucleophilic fluorination on 4 with 18F−/K[2.2.2]
(kryptofix, 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.
8]hexacosane) in the presence of K2CO3, for 25 min. After
a solid phase extraction, the resulting 3-chloro-4[18F]
fluoronitrobenzene ([18F]5) is subjected to a reduction
using sodium borohydride in the presence of palladium
on carbon, thus furnishing the desired 3-chloro-4[18F]
fluoroaniline ([18F]6). The final step is a BOP-mediated
condensation of aniline 6 with 7 to provide [18F]afatinib
in high yields (up to 3.5 GBq) and high specific activity
(223 ± 38 GBq/μmol) after HPLC purification. Initial
in vivo stability as well as ex vivo biodistribution studies
demonstrated excellent in vivo stability of the tracer and
uptake in NSCLC xenografted mice, although no large dif-
ferences with regard to uptake between wild-type (WT)
and the exon 19 deleted mutant of EGFR were observedin ex vivo biodistribution studies, therefore necessitating
further PET studies described in this work [21].
Xenograft characterization
Three NSCLC cell lines were selected for the generation
of xenografts and the in vivo evaluation of [11C]erlotinib
and [18F]afatinib, each expressing a specific EGFR muta-
tion and thus providing a representative overview of mu-
tations found in clinical cases of NSCLC [24]. Firstly, an
insensitive reference cell line which expresses EGFR wild
type was selected (A549). Next, a cell line (H1975) which
expresses a double mutant of EGFR (L858R/T790M);
the first being one of the common sensitizing point mu-
tation in exon 21 (L858R) and the second a mutation as-
sociated with acquired resistance to erlotinib therapy
(T790M in exon 20). Finally, a cell line was selected
which is highly sensitive to TKI treatment, namely the
HCC827 cell line which harbors a deletion in exon 19
(delE746-A750). The sensitivity of these cell lines to-
wards the two inhibitors has been clearly described in
literature [19,25,26]. The results of in vitro studies and
in vivo xenograft experiments demonstrated excellent ef-
ficacy of both inhibitors. The double mutant H1975 cells
were shown to be resistant to treatment with erlotinib
but showed a reduction in tumor growth rate in vivo
upon afatinib treatment, although significantly less than
HCC827. Finally, neither erlotinib nor afatinib showed
any in vitro or in vivo efficacy to the wild-type A549
cells and xenografts, which despite expressing EGFR are
not dependent on the ErbB signaling network for
proliferation.
To fully characterize these cell lines before the start of
PET imaging studies, they were xenografted onto athy-
mic nu/nu mice and immunohistochemistry and sequen-
cing were performed on the xenograft material. EGFR
expression was found in all lines (Figure 2) and although
immunohistochemistry is a semi-quantitative technique,
staining appeared most intense in HCC827 xenografts.
The EGFR mutations of the xenografts, as described be-
fore, were confirmed by sequencing. Finally, the tumors
were stained for the expression of P-gp, a drug efflux
transporter, for which erlotinib and afatinib are known
substrates [27,28]. The staining indicated that this efflux
transporter was most extensively expressed by HCC827
xenografts.
PET imaging with [11C]erlotinib and [18F]afatinib in lung
cancer xenografts
PET imaging was performed with both tracers in all
three xenograft models to determine whether the irre-
versible inhibitor shows better tumor targeting. In order
to have a proper region for the background tissue, the
mice were grafted with a single tumor on the left flank.
In this manner, the right flank of the animal served as
Figure 2 Immunohistochemical staining of NSCLC xenograft lines as used in PET studies. Images depicted at 5× magnification. Mutations:
A549 (wild type), H1975 (L858R/T790M), and HCC827 (exon 19 deletion).
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except that it is devoid of tumor cells. Both tumor and
background were manually outlined on the basis of an
additional [18F]FDG scan, which was performed directly
after the TKI-PET scan was finished. Percentage injected
dose per gram of tissue can be directly derived from
these PET scans as a quantitative measure of uptake.
The images and time-activity-curves (TACs, depicting
activity concentration over time) of the PET study are
shown in Figure 3, and the tumor-to-background ratios
(resulting from a comparison between activity concen-
tration in the tumor and reference tissue) are summa-
rized in Table 1. Since [18F]afatinib has a longer half-life
than [11C]erlotinib, [18F]afatinib could be scanned for
longer time periods. However, no significant changes
were observed in this later frame with regard to uptake.
The images shown (Figure 3) are from the last 30 min of
the scan (60 to 90 min for [11C]erlotinib and 90 to
120 min for [18F]afatinib), representing the highest
tumor-to-background ratios. High uptake is observed in
the liver and kidneys for both tracers, which is common for
IV-administered small molecular PET tracers as these or-
gans represent the major excretion and catabolic routes.
The most striking difference between the two tracers is that
[11C]erlotinib displays significantly slower kinetics when
compared to [18F]afatinib, irrespective of the xenograft
line studied. Indeed, [11C]erlotinib (reversible inhibitor)
reaches its peak uptake in the tumor (HCC827) at 25 min
of 3.2 ± 0.3%ID/g PI, whereas [18F]afatinib (irreversible in-
hibitor) activity concentration in the tumor (HCC827) is
already at a maximum of 1.2 ± 0.2%ID/g at 10 min PI, in-
dicating faster kinetics and/or clearance (Figure 3). This
results in a higher activity concentration in the case of
[11C]erlotinib in all tissues of interest (tumor and back-
ground) when compared to [18F]afatinib.Regarding the general imaging properties, both tracers
appear to have a similar uptake pattern across the vari-
ous xenograft lines with their distinguished mutational
status (Figure 3). In xenografts expressing wild-type
EGFR (A549), [11C]erlotinib does not show any selective
accumulation which is comparable with previous litera-
ture reported on this tracer [16]. [18F]afatinib demon-
strates a modest, yet statistically significant uptake in
A549 cells (Table 1, entry 4).
In the double mutant xenografts (H1975), which har-
bor a sensitizing mutation (L858R), and an acquired re-
sistance mutation (T790M), no selective uptake was
observed for either tracer (Table 1, entries 2 and 5). This
result is in good accordance with the efficacy of erloti-
nib, as it shows no therapeutic effect in this xenograft
model. However, afatinib showed a modest but signifi-
cant reduction in tumor growth rate of H1975 xeno-
grafts [20,25], whereas no significant tumor uptake of
[18F]afatinib was observed (Figure 3).
Both [11C]erlotinib and [18F]afatinib demonstrate best
uptake in the HCC827 xenografts. [18F]afatinib demon-
strates a slightly higher tumor-to-background ratio than
[11C]erlotinib (Table 1, entries 3 and 6). This data demon-
strates the ability of TKI-PET to image TKI uptake in
these tumors in an effective manner. It was previously
demonstrated that uptake of [11C]erlotinib in HCC827
xenografts could be blocked by the addition of unlabeled
erlotinib [29]. To ascertain whether imaging should be
performed at high specific activity in the case of [18F]afati-
nib (4 to 6 MBq, 0.017 to 0.026 nmol of afatinib), PET im-
aging with co-administration of unlabeled afatinib (100 to
6,000 ng) in a bolus IV injection with the tracer was per-
formed in the HCC827 xenograft line. This demonstrated
that the uptake of the tracer was blocked to the back-
ground level with a 100-ng addition of afatinib (Table 2).
Figure 3 PET images and TACs of [11C]erlotinib (top) and [18F]afatinib (bottom). Circle indicates tumor position and arrow indicates reference
tissue. [11C]erlotinib images summed from 60 to 90 min, [18F]afatinib images from 90 to 120 min. TACs are averaged over three animals. Mutations:
A549 (wild type), H1975 (L858R/T790M), and HCC827 (exon 19 deletion). Tumor and background were manually outlined on the basis of an additional
[18F]FDG scan, which was performed directly after the TKI-PET scan was finished.
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sults described above. Firstly, the absolute uptake (%ID/g,
Figure 3) of [18F]afatinib in HCC827 xenografts is lower
in comparison with uptake of [11C]erlotinib, where this
was expected to be at least comparable, based on the re-
spective affinities of the compounds for EGFR. Immuno-
histochemistry demonstrated that HCC827 cells have a
high P-gp expression and thus, there is a possibility that
drug efflux is playing a role in this xenograft line. How-
ever, differences in biophysical properties such as lipophi-
licity, basicity, or passive permeation may also influence
the apparent uptake of these compounds. Secondly, when
comparing the reversible [11C]erlotinib with irreversible
[18F]afatinib, no significant differences are observed with
regard to the kinetic profile displayed in the TACs for this
xenograft model (Figure 3). Thirdly, no differential uptake
compared to the background of [18F]afatinib was ob-
served in H1975 tumors despite the fact that afatinib is
therapeutically effective in this xenograft line (Figure 3).Finally, in the wild-type xenograft line (A549), no uptake
of [11C]erlotinib was observed, while [18F]afatinib did
show modest uptake (Figure 3). This could be due to dif-
ferences in retention which might be attributed to the bio-
physical differences between the two tracers, the ability of
[18F]afatinib to bind covalently to additional targets
(HER2 and ERBB4 next to EGFR) or differences in affinity
for efflux transporters. In an attempt to gain further
insight into the role of P-gp in PET tracer uptake, an im-
aging study was performed in the presence of an efflux
transporter inhibitor.
Influence of drug efflux transporter on tracer uptake
P-glycoprotein (or multidrug resistance protein 1; MDR1)
is an ATP-dependent efflux pump that is responsible for
the transport of foreign substrates out of the cells and
thereby serves as a defense mechanism against these sub-
strates. P-gp expression was previously observed for
H1975 and HCC827 using immunohistochemistry and
Table 1 Summary of tumor-to-background ratios






A549 1 1.0 ± 0.3 4 1.5 ± 0.3*
H1975 2 0.9 ± 0.3 5 0.8 ± 0.2
HCC827 3 1.9 ± 0.5* 6 2.3 ± 0.4*
Tariquidar blocked (15 mg/kg)
A549 7 1.2 ± 0.3 10 1.3 ± 0.3*
H1975 8 1.0 ± 0.2 11 0.8 ± 0.2
HCC827 9 1.8 ± 0.3* 12 1.9 ± 0.4*
Comparison of tumor-to-background ratios in non-blocked (1 to 6) and
blocked situation (7 to 12) ratios determined in the last frame of the scans (60
to 90 min for [11C]erlotinib and 90 to 120 min for [18F]afatinib) and averaged
over three animals. P-gp blocking was performed with 15 mg/kg tariquidar.
*Tumor-to-background is statistically significant (P < 0.05, Student’s t-test for
paired data). Mutations: A549 (wild type), H1975 (L858R/T790M), and HCC827
(exon 19 deletion).
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could result in an increased uptake of the PET tracers
[27,28].
Dynamic PET imaging was performed while blocking
P-gp using tariquidar (15 mg/kg). Tariquidar was suc-
cessfully applied in previous PET studies to block P-gp
[23,30], although it was recently demonstrated that is
also an inhibitor of breast cancer resistance protein
BCRP, another ATP-binding cassette (ABC) family efflux
transporter [31]. Tracer uptake in brain was also moni-
tored as the blood-brain barrier has, among other efflux
transporters, high P-gp expression. Pre-treatment with
tariquidar resulted in an increased uptake of both [11C]
erlotinib and [18F]afatinib in the brain (Figure 4), thus
showing that biodistribution of both compounds (both
P-gp substrates) can be influenced by P-gp blockers.
The TACs of the pre-blocked mice bearing the same
tumor models as in the non-blocked condition are
depicted in Figure 5. In the wild-type xenograft (A549),Table 2 Blocking of [18F]afatinib uptake in HCC827
xenografts
Added dose of afatinib (ng) Tumor-to-background ratio
0 2.3 ± 0.4*
100 1.1 ± 0.4
300 1.0 ± 0.3
1,000 0.9 ± 0.2
3,000 0.9 ± 0.3
Tumor-to-background ratio after a bolus injection of [18F]afatinib with added
isotopically unmodified afatinib. Ratios determined in the last frame of the
scans (90 to 120 min) and averaged over three animals.*Tumor-to-background
is statistically significant (P < 0.05, Student’s t-test for paired data). HCC827
xenografts harbor an exon 19 deleted variant of EGFR.a minor increase of [11C]erlotinib tumor accumulation
was observed which is also reflected in the tumor-to-
background ratio (Table 1, entry 7), although this was
not found to be statistically significant. In this xenograft
model, a higher uptake was observed after treatment
with tariquidar in both the tumor and the background
(compare Figure 5 with Figure 3). [18F]afatinib also
demonstrates a higher absolute uptake of activity (%ID/
g) in the tumor and background and no washout was
observed in either tissues. Apparently, the blocking of
the efflux transporter systems with tariquidar resulted in
better tissue trapping of [18F]afatinib (Figure 5).
The double mutant (H1975) showed no uptake in the
tumor upon P-gp inhibition for [11C]erlotinib (Table 1,
entry 8) similar to the unblocked situation (Table 1,
entry 2). For [18F]afatinib, a higher activity concentration
was observed (Figure 5), although the tumor-to-
background ratio remained similar to the non-blocked
situation (Table 1, entries 5 and 11).
Finally, in the HCC827 xenograft, no differences were
observed for [11C]erlotinib in tumor-to-background ratio
(Table 1, entries 3 and 9). In the case of [18F]afatinib, a
substantial increase of activity concentration was observed
(maximal activity concentration 1.9 ± 0.1%ID/g vs 1.2 ±
0.2%ID/g, Figure 3), although this did not lead to higher
tumor-to-background ratio due to a similar increase in the
background tissue. It does, however, indicate that [18F]afa-
tinib is influenced by efflux transporters to a larger extent
than [11C]erlotinib. This is also observed in the kinetics of
[18F]afatinib binding, as these are significantly affected. Re-
tention of activity was observed in the HCC827 model in
the TAC (Figure 5). This observation is in line with the ir-
reversible mode of binding of afatinib.
An important observation from the blocking study is
a moderate increase of activity in all tissues studied for
[18F]afatinib (Figure 5). This may be caused by an in-
crease of activity in the blood pool, under P-gp block-
ing conditions, and hence increased delivery of [18F]
afatinib to tissues. This can be explained by the inverse
function of P-gp in the intestinal lumen where it nor-
mally extracts xenobiotics from the blood [32]. This ex-
traction may be reduced due to the blocking of P-g by
tariquidar, resulting in a higher concentration of [18F]
afatinib in the blood. The relatively large increase of
[18F]afatinib accumulation in the HCC827 tumors indi-
cates that efflux transporters play a significant role in
the apparent uptake or efflux of afatinib from these tu-
mors. In the EGFR wild-type xenograft A549, showing
low P-gp expression, this difference was much less pro-
nounced (Figure 5).
Interestingly the [18F]afatinib TACs in the A549 and
HCC827 xenografts demonstrate an irreversible character
with regard to uptake of [18F]afatinib under P-gp blocking
conditions (Figure 5). It might well be that efflux by P-gp
Figure 4 Whole brain TACs of [11C]erlotinib (left) and [18F]afatinib (right) before and after tariquidar pre-treatment. TACs are averaged
over three animals.
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than the irreversible binding, resulting in what appears to
be reversible kinetics. This effect is not observed for [11C]
erlotinib and is in line with a reversible mode of binding.
The H1975 xenograft demonstrated no uptake in the
blocked or non-blocked situation, which was unexpected
on the basis of affinity.
The irreversible binding of afatinib to EGFR-WT and
EGFR-T790M was demonstrated in vitro by Solca et al.
in several experiments, including mass spectrometry and
X-ray crystallography of afatinib bound to EGFR-
T790M, where a covalent bond between afatinib and
EGFR-T790M was demonstrated [19]. The results from
the current PET studies suggest that the in vivo tumor
uptake of [11C]erlotinib and [18F]afatinib is influenced
by P-gp expression levels and tracer uptake is not com-
pletely predictive for the therapeutic efficacy in the
H1975 xenograft line. One of the reasons might be thatFigure 5 TACs of [11C]erlotinib (top) and [18F]afatinib (bottom) after t
A549 (wild type), H1975 (L858R/T790M), and HCC827 (exon 19 deletion). Tum
[18F]FDG scan, which was performed directly after the TKI-PET scan was finishin the current study, [11C]erlotinib and [18F]afatinib are
administered IV at a tracer dose (μg/kg), while efficacy is
tested after oral administration at a therapeutic dose
(mg/kg). This justifies further characterization of [11C]
erlotinib and [18F]afatinib in PET studies under thera-
peutic dosage conditions.
Conclusions
Both [11C]erlotinib and [18F]afatinib are useful TKI-PET
tracers for imaging treatment-sensitive xenografts har-
boring exon 19 deletion mutations in EGFR. The good
tumor-to-background ratios could in the future be used
in clinical decision making for both tracers. The differ-
ence between a reversible and irreversible inhibitor
could not be demonstrated within a standard PET im-
aging situation as both tracers showed similar tumor up-
take kinetics. However, when the drug efflux transporter
P-gp is blocked, increased tumor uptake is observed andariquidar treatment. TACs are averaged over three animals. Mutations:
or and background were manually outlined on the basis of an additional
ed.
Slobbe et al. EJNMMI Research  (2015) 5:14 Page 11 of 12under those conditions [18F]afatinib reveals different
kinetics in the HCC827 model suggestive of irreversible
binding. This shows that preclinical TKI-PET imaging
can be used to compare tumor-targeting properties and
tumor kinetics of TKIs, making it a valuable tool for
drug design and selection.
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